TCG Crossover Management's $85 Million Bet on Amylyx: A Transformational Year Ahead?

TCG Crossover Management, a California-based biotech fund, has increased its stake in Amylyx Pharmaceuticals by buying 300,000 shares during the third quarter, raising its position to 6.2 million shares with a market value of $84.9 million. Amylyx's stock has surged 180% over the past year, and the fund's co-CEOs are optimistic about the company's prospects, expecting a "transformational" year ahead.